Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03013504 2024-11-06

TROIKA

Phase 3 Completed

503 enrolled

Breast

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast

Breast Neoplasms

NCT04187898 2024-09-19

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Phase 1 Completed

59 enrolled

Breast

Breast Neoplasms, Neutropenia

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Phase 3 Completed

108 enrolled 7 charts

Breast

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Phase 3 Completed

500 enrolled 28 charts 3 FDA

Breast

Breast Neoplasms

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Phase 2 Recruiting

79 enrolled

Breast

Breast Neoplasms

NCT05207514 2024-05-17

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Phase 3 Terminated

26 enrolled

Breast

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

Phase 2 Completed

257 enrolled

Breast

Breast Neoplasms

NCT06227117 2024-03-19

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Completed

24 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03752723 2024-03-05

KEYNOTE-899

Phase 1/2 Completed

84 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Phase 2 Completed

126 enrolled 16 charts

Breast

Breast Neoplasms

NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Phase 1 Terminated

10 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT00493870 2023-03-02